ICM
VIVO

IMS Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

IMS Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-326
Closed -$5K – 371
2018
Q3 		$5K Buy
+326
New +$5.05K ﹤0.01% 357
2014
Q1 		– Sell
-7,676
Closed -$204K – 180
2013
Q4 		$204K Buy
+7,676
New +$189K 0.26% 124

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

IMS Capital Management's VIVO Position: Q4 2018 in Review

IMS Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q4 2018, closing a stake of 326 shares — an estimated $5K sold.

IMS Capital Management first reported a position in VIVO in Q4 2013 and held it in 2 quarters. The position peaked at $204K in Q4 2013. 191 funds tracked by Wall St. Rank hold VIVO as of Q4 2018.

  • IMS Capital Management reported no remaining Meridian Bioscience Inc position as of Q4 2018 after selling out during the quarter.
  • IMS Capital Management sold 326 Meridian Bioscience Inc shares in Q4 2018, an estimated $5K.
  • IMS Capital Management first reported a position in Meridian Bioscience Inc in Q4 2013 and held it in 2 quarters.
  • IMS Capital Management's Meridian Bioscience Inc position peaked at $204K in Q4 2013.
  • 191 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2018.

Based on IMS Capital Management's 13F filing for Q4 2018, filed 7 Feb 2019.